ANN ARBOR, Mich., Sept. 24, 2019 — Eversight today announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost.
“The more time ophthalmologists can spend focused on patients and procedures, the better. As preference for DORC grew, Eversight saw a viable opportunity to further simplify preoperative preparation,” said Michael Titus, Vice President of Clinical Operations, Eversight. “The preloaded DORC tube arrives onsite ready for the operating room. This natural evolution of Eversight’s tissue services demonstrates our continued work to address procedural needs and improve patients’ lives.”
The DORC injector demonstrates low endothelial cell count loss1 and is the instrument of choice for many eye surgeons. Developed by Gerrit R.J. Melles, M.D., Ph.D., and the Dutch Ophthalmic Research Center (DORC), the curved glass tube provides an ergonomic injection angle and its long, tapered end can advance further into the anterior chamber for smooth, precise delivery of the donor corneal graft. Importantly, the DORC tube requires a small 2.4mm incision that may facilitate sutureless procedures, improve healing and enable surgeons to perform multiple procedures during a single case.
“With Eversight’s new preloaded DMEK option, there is virtually nothing that I or my clinical staff have to do to prepare the tissue,” said Parag A. Majmudar, M.D., Chicago Cornea Consultants, a DORC user since 2013. “There is also no need to alter the surgical procedure in any way, such as enlarging the incision. Preloaded DORC creates a seamless DMEK insertion experience that minimizes complications for fellows and seasoned surgeons alike.”
About Eversight
Eversight is nonprofit organization with a mission to restore sight and prevent blindness through the healing power of donation, transplantation and research. The Eversight network is responsible for recovering, evaluating and providing human eye tissue for transplantation; supporting research into the causes and cures of blinding eye conditions; promoting donation awareness through public and professional education; and providing humanitarian aid to people around the world in need of corneal transplantation. Operating in Connecticut, Illinois, Michigan, New Jersey, Ohio and South Korea, Eversight works in collaboration with surgeons, researchers, academic medical centers and eye banks across the United States and abroad. For more information, visit eversightvision.org.
References
1 Droutsas K, Lazaridis A, Kymionis GD, et al. Comparison of endothelial cell loss and complications following DMEK with the use of three different graft injectors. Eye (Lond). 2018;32(1):19–25. doi:10.1038/eye.2017.237
Media Contact
Mackenzie Mohr
Marketing & Communications Specialist
O: (734) 780-2673
